BankPlus Trust Department’s Vertex Pharmaceuticals VRTX Stock Holding History

BankPlus Trust Department’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$702K	Sell	1,414 -19	-1%	-$8.42K	0.16%	107
2026 Q1	$640K	Buy	1,433 +77	+6%	+$35.9K	0.17%	111
2025 Q4	$615K	Buy	1,356 +33	+2%	+$14.2K	0.16%	108
2025 Q3	$518K	Sell	1,323 -18	-1%	-$7.52K	0.14%	117
2025 Q2	$597K	Sell	1,341 -15	-1%	-$6.91K	0.18%	99
2025 Q1	$657K	Sell	1,356 -23	-2%	-$10.7K	0.22%	86
2024 Q4	$555K	Buy	+1,379	New	+$639K	0.18%	98

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BankPlus Trust Department's VRTX Position: Q2 2026 in Review

BankPlus Trust Department reduced its Vertex Pharmaceuticals (VRTX) stake by 1.3% in Q2 2026, selling an estimated $8.42K and leaving 1,414 shares worth $702K. The position accounts for 0.16% of the portfolio, ranked #107.

BankPlus Trust Department first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

BankPlus Trust Department held 1,414 shares of Vertex Pharmaceuticals worth $702K as of Q2 2026.
BankPlus Trust Department sold 19 Vertex Pharmaceuticals shares in Q2 2026, an estimated $8.42K.
Vertex Pharmaceuticals made up 0.16% of BankPlus Trust Department's portfolio in Q2 2026, its #107 holding.
BankPlus Trust Department first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on BankPlus Trust Department's 13F filing for Q2 2026, filed 28 Jul 2026.